Cryolife Inc (CRY): C Elkins Ronald , director of Cryolife Inc sold 1,000 shares on Apr 15, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $12.00 per share for a total value of $12,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 9, 2016, C Elkins Ronald (director) sold 2,000 shares at $11.18 per share price.On Mar 4, 2016, James P Mackin (CEO) purchased 10,000 shares at $10.91 per share price.Also, On Mar 1, 2016, David C Gale (VP, Research & Development) sold 150 shares at $9.97 per share price.On Feb 23, 2016, Scott B Capps (VP, Clinical Research) sold 15,000 shares at $10.30 per share price.
Cryolife Inc: On Monday, Apr 18, 2016 heightened volatility was witnessed in Cryolife Inc which led to swings in the share price. The shares opened for trading at $11.92 and hit $12.7 on the upside , eventually ending the session at $12.57, with a gain of 4.84% or 0.58 points. The heightened volatility saw the trading volume jump to 2,23,139 shares. The 52-week high of the share price is $12.7 and the company has a market cap of $409 M . The 52-week low of the share price is at $8.94.
Company has been under the radar of several Street Analysts.Cryolife Inc is Initiated by Canaccord Genuity to Buy and the brokerage firm has set the Price Target at $14. The Rating was issued on Apr 13, 2016.
Currently the company Insiders own 13.36% of Cryolife Inc shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by 1.75%.Institutional Investors own 52.21% of Cryolife Inc shares.During last six month period, the net percent change held by insiders has seen a change of 1.75%.
CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.